Engineering building blocks for self-assembling protein nanoparticles

Like natural viruses, manmade protein cages for drug delivery are to be ideally formed by repetitive subunits with self-assembling properties, mimicking viral functions and molecular organization. Naturally formed nanostructures (such as viruses, flagella or simpler protein oligomers) can be engineered to acquire specific traits of interest in biomedicine, for instance through the addition of cell targeting agents for desired biodistribution and specific delivery of associated drugs. However, fully artificial constructs would be highly desirable regarding finest tuning and adaptation to precise therapeutic purposes. Although engineering of protein assembling is still in its infancy, arising principles and promising strategies of protein manipulation point out the rational construction of nanoscale protein cages as a feasible concept, reachable through conventional recombinant DNA technologies and microbial protein production.

[1]  Eileen Ingham,et al.  Production of self-assembling biomaterials for tissue engineering , 2009, Trends in biotechnology.

[2]  J. Enbäck,et al.  Tumour-homing peptides: tools for targeting, imaging and destruction. , 2007, Biochemical Society Transactions.

[3]  A. de Marco,et al.  Characterization of the aggregates formed during recombinant protein expression in bacteria , 2005, BMC Biochemistry.

[4]  Marilena Loizidou,et al.  Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.

[5]  A. Villaverde,et al.  Nonviral gene delivery to the central nervous system based on a novel integrin-targeting multifunctional protein. , 2003, Human gene therapy.

[6]  Shaker A Mousa,et al.  Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. , 2010, Pharmacology & therapeutics.

[7]  Kit S Lam,et al.  From combinatorial chemistry to cancer-targeting peptides. , 2007, Molecular pharmaceutics.

[8]  E. Wagner.  Strategies to Improve DNA Polyplexes for in Vivo Gene Transfer: Will “Artificial Viruses” Be the Answer? , 2004, Pharmaceutical Research.

[9]  Liping Yu,et al.  Targeted Drug Delivery to Hepatocarcinoma In vivo by Phage-Displayed Specific Binding Peptide , 2010, Molecular Cancer Research.

[10]  X. Sun,et al.  Rational design of responsive self-assembling peptides from native protein sequences. , 2010, Biomacromolecules.

[11]  Antonio Villaverde,et al.  Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview , 2008 .

[12]  Li Shi,et al.  Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers , 2010, Expert opinion on drug delivery.

[13]  Fabrizio Gelain,et al.  Slow and sustained release of active cytokines from self-assembling peptide scaffolds. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[14]  M. McPherson,et al.  Recombinant self-assembling peptides as biomaterials for tissue engineering , 2010, Biomaterials.

[15]  M. McPherson,et al.  Bioproduction and characterization of a pH responsive self‐assembling peptide , 2009, Biotechnology and bioengineering.

[16]  Antonio Villaverde,et al.  Nanostructured bacterial materials for innovative medicines. , 2010, Trends in microbiology.

[17]  Thomas L Andresen,et al.  Liposomal cancer therapy: exploiting tumor characteristics , 2010, Expert opinion on drug delivery.

[18]  A. Epenetos,et al.  Antibodies targeting cancer stem cells: A new paradigm in immunotherapy? , 2009, mAbs.

[19]  Esther Vázquez,et al.  Microbial factories for recombinant pharmaceuticals , 2009 .

[20]  Jun Wang,et al.  Protein-based nanomedicine platforms for drug delivery. , 2009, Small.

[21]  A. Villaverde,et al.  Molecular organization of protein-DNA complexes for cell-targeted DNA delivery. , 2000, Biochemical and biophysical research communications.

[22]  Surya Singh.  Nanomedicine-nanoscale drugs and delivery systems. , 2010, Journal of nanoscience and nanotechnology.

[23]  Wim E. Hennink,et al.  Artificial viruses: a nanotechnological approach to gene delivery , 2006, Nature Reviews Drug Discovery.

[24]  A. Villaverde,et al.  Peptide-mediated DNA condensation for non-viral gene therapy. , 2009, Biotechnology advances.

[25]  K. L. Douglas.  Toward Development of Artificial Viruses for Gene Therapy: A Comparative Evaluation of Viral and Non‐viral Transfection , 2008, Biotechnology progress.

[26]  Antonio Villaverde,et al.  Learning about protein solubility from bacterial inclusion bodies , 2009, Microbial cell factories.

[27]  Laia Acarin,et al.  Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector , 2006, BMC Neuroscience.

[28]  T. Tan,et al.  Self-assembling peptide nanofiber scaffolds for controlled release governed by gelator design and guest size. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[29]  S. Parveen,et al.  Polymeric nanoparticles for cancer therapy. , 2008, Journal of drug targeting.

[30]  E. Vázquez,et al.  Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. , 2010, Biomaterials.

[31]  E. Vázquez,et al.  Peptide-assisted traffic engineering for nonviral gene therapy. , 2008, Drug discovery today.

[32]  Erkki Ruoslahti,et al.  Targeting of drugs and nanoparticles to tumors , 2010, The Journal of cell biology.

[33]  Raul Machado,et al.  Thermoresponsive self-assembled elastin-based nanoparticles for delivery of BMPs. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[34]  André Pèlegrin,et al.  Cell-penetrating and cell-targeting peptides in drug delivery. , 2008, Biochimica et biophysica acta.

[35]  A. Villaverde,et al.  Friendly production of bacterial inclusion bodies , 2010 .

[36]  G. Mills,et al.  Future of personalized medicine in oncology: a systems biology approach. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  E. Vázquez,et al.  Modular protein engineering in emerging cancer therapies. , 2009, Current pharmaceutical design.

[38]  A. Villaverde,et al.  Amyloid-like properties of bacterial inclusion bodies. , 2005, Journal of molecular biology.

[39]  A. Middelberg,et al.  The chromatography‐free release, isolation and purification of recombinant peptide for fibril self‐assembly , 2009, Biotechnology and bioengineering.

[40]  Lisa Brannon-Peppas,et al.  Micro- and nanofabrication methods in nanotechnological medical and pharmaceutical devices , 2006, International journal of nanomedicine.

[41]  T. Matsunaga,et al.  Novel Method for Selection of Antimicrobial Peptides from a Phage Display Library by Use of Bacterial Magnetic Particles , 2008, Applied and Environmental Microbiology.

[42]  H. Tjalsma.  Identification of biomarkers for colorectal cancer through proteomics-based approaches , 2010, Expert review of proteomics.

[43]  S. Deutscher.  Phage display in molecular imaging and diagnosis of cancer. , 2010, Chemical reviews.

[44]  J. Veciana,et al.  Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. , 2010, Nanomedicine.

[45]  C. Napoli,et al.  Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. , 2007, European journal of cancer.

[46]  Trevor Douglas,et al.  Biological Containers: Protein Cages as Multifunctional Nanoplatforms , 2007 .

[47]  A. Villaverde,et al.  The Functional Quality of Soluble Recombinant Polypeptides Produced in Escherichia coli Is Defined by a Wide Conformational Spectrum , 2008, Applied and Environmental Microbiology.

[48]  E. Vázquez,et al.  Protein Aggregation and Soluble Aggregate Formation Screened by a Fast Microdialysis Assay , 2010, Journal of biomolecular screening.

[49]  K. Brown.  Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. , 2010, Current pharmaceutical design.

[50]  S. Sidhu.  Phage display in pharmaceutical biotechnology. , 2000, Current opinion in biotechnology.

[51]  E. Vázquez,et al.  Membrane-active peptides for non-viral gene therapy: making the safest easier. , 2008, Trends in biotechnology.

[52]  K. Jensen-Pergakes,et al.  Evolving phage vectors for cell targeted gene delivery. , 2002, Current pharmaceutical biotechnology.

[53]  A. Villaverde,et al.  Protein quality in bacterial inclusion bodies. , 2006, Trends in biotechnology.

[54]  T. Vo‐Dinh,et al.  Cellular Uptake and Photodynamic Activity of Protein Nanocages Containing Methylene Blue Photosensitizing Drug , 2010, Photochemistry and photobiology.

[55]  A. Villaverde,et al.  Modular protein engineering for non-viral gene therapy. , 2004, Trends in biotechnology.

[56]  I. Yacoby,et al.  Killing cancer cells by targeted drug-carrying phage nanomedicines , 2008, BMC biotechnology.

[57]  R. Falconer,et al.  Expression and purification of a nanostructure-forming peptide. , 2008, Journal of biotechnology.

[58]  Gunnar P. H. Dietz,et al.  Delivery of bioactive molecules into the cell: the Trojan horse approach , 2004, Molecular and Cellular Neuroscience.

[59]  A. Villaverde.  Nanotechnology, bionanotechnology and microbial cell factories , 2010, Microbial cell factories.

[60]  Alain Van Dorsselaer,et al.  Peptides as tools and drugs for immunotherapies , 2007, Journal of peptide science : an official publication of the European Peptide Society.

[61]  T. Tan,et al.  Nanofibrous scaffold from self-assembly of beta-sheet peptides containing phenylalanine for controlled release. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[62]  Kevin G. Rice,et al.  Peptide-guided gene delivery , 2007, The AAPS Journal.

[63]  A. Villaverde,et al.  Engineering nuclear localization signals in modular protein vehicles for gene therapy. , 2003, Biochemical and biophysical research communications.